AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Key points
- AbbVie (NYSE:ABBV) reported third-quarter 2026 revenue of $17.404 billion, up 10.3% year over year.
- GAAP diluted EPS reached $2.37, while adjusted diluted EPS increased to $3.82, with both measures more than doubling from the prior-year period.
- AbbVie raised its 2026 adjusted EPS guidance to $13.95–$13.99 and announced a 5.2% dividend increase beginning in February 2027.
AbbVie (NYSE:ABBV) reported third-quarter 2026 net revenue of $17.404 billion, up 10.3% year over year, while GAAP diluted earnings per share increased to $2.37.
Both GAAP and adjusted diluted EPS more than doubled from the prior-year period, reaching $2.37 and $3.82, respectively, with revenue growth across several major business segments.
The company reported that immunology and neuroscience products contributed to quarterly growth, with reported revenue increasing 16.3% and 19.4%, respectively.
Aesthetics revenue declined 1.4%, while both GAAP and adjusted diluted EPS included a $0.11 unfavorable impact from acquired in-process research and development and milestone expenses.
AbbVie raised its 2026 adjusted EPS guidance to $13.95–$13.99 from its previous range of $13.76–$13.96, and announced a 5.2% dividend increase beginning with the February 2027 payment.
The company also completed its acquisition of Apogee Therapeutics and received FDA approvals for Skyrizi subcutaneous induction in Crohn's disease and Juvmo for Parkinson's disease.
AbbVie develops and commercializes prescription medicines across immunology, oncology, neuroscience and aesthetics, with products including Skyrizi, Rinvoq, Botox and Vraylar.
Frequently asked questions
More from United States
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
Church & Dwight quarterly revenue edges higher to $1.60 billion
